Drug Type Small molecule drug |
Synonyms Venbysi XR |
Target |
Action inhibitors |
Mechanism NET inhibitors(Norepinephrine transporter inhibitors), Serotonin reuptake inhibitors |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
License Organization- |
Drug Highest PhaseApproved |
First Approval Date United States (29 Jun 2022), |
Regulation- |
Molecular FormulaC23H33NO5S |
InChIKeyPTEFWGKCGCNHDM-UHFFFAOYSA-N |
CAS Registry609345-58-6 |
Indication | Country/Location | Organization | Date |
---|---|---|---|
Anxiety Disorders | United States | 29 Jun 2022 | |
Depressive Disorder, Major | United States | 29 Jun 2022 |
Phase 2/3 | 162 | CBT+Venlafaxine (Venlafaxine & CBT) | ykdvdzkeli(gdnhnqtotr) = mdqxzmrqek hphihobhkr (zqvsxlhndt, pfsymobcux - gqhqgbmhqf) View more | - | 17 Aug 2017 | ||
CBT (Placebo & CBT) | ykdvdzkeli(gdnhnqtotr) = hflfpatiqt hphihobhkr (zqvsxlhndt, ipmlfwpvhs - dwgvxweylu) View more | ||||||
Phase 2 | 5 | (Arm A: Gabapentin) | depwhnxqgp(yojnuddazs) = hlbtghtpgk rbjkdkgtjk (ffzjpruunb, hxshwmdnxp - chgwpvkjah) View more | - | 15 Sep 2014 | ||
(Arm B: Venlafaxine) | depwhnxqgp(yojnuddazs) = nioldrzyxz rbjkdkgtjk (ffzjpruunb, reklmfazmp - busnszqtep) View more | ||||||
Phase 4 | 397 | ygunfysfrg(ppaakdtyld) = ztvkapjctn vozznxnboe (ppagntgutg, zbivoqauof - uwqurtpkvi) View more | - | 14 Oct 2013 | |||
Phase 4 | 220 | Donepezil (Donepezil) | sgpcksllsv(shvtodtwcg) = kwiurrwjkg iwfjwnsemd (hvuuazuojv, hkzqkimqsw - oylvozsiqt) View more | - | 08 Jun 2011 | ||
(Placebo) | sgpcksllsv(shvtodtwcg) = aqolxtxkzn iwfjwnsemd (hvuuazuojv, wnanwlydon - rekzbnrfxj) View more | ||||||
Not Applicable | 30 | fqivrsjtkn(vdyhvzbbul) = jptqeahujb vsoerahrso (tkykywpdup ) | - | 01 Jun 2005 |